PolyPid Ltd.

NasdaqCM:PYPD 株式レポート

時価総額:US$22.5m

PolyPid 過去の業績

過去 基準チェック /06

PolyPid has been growing earnings at an average annual rate of 3.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

主要情報

3.1%

収益成長率

83.2%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率n/a
株主資本利益率-1,542.9%
ネット・マージンn/a
次回の業績アップデート13 Nov 2024

最近の業績更新

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

PolyPid: Strong Pipeline, Close Catalysts

Apr 19

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Mar 18
Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Nov 08
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Jul 15
We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

収支内訳

PolyPid の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:PYPD 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 240-25518
31 Mar 240-24617
31 Dec 230-24716
30 Sep 230-24716
30 Jun 230-28819
31 Mar 230-341023
31 Dec 220-401128
30 Sep 220-461333
30 Jun 220-471334
31 Mar 220-461333
31 Dec 210-431331
30 Sep 210-411126
30 Jun 210-371123
31 Mar 210-461120
31 Dec 200-43917
30 Sep 200-42815
30 Jun 200-37615
31 Mar 200-19514
31 Dec 190-13414
31 Dec 1800613
31 Dec 170-59410
30 Sep 170-2039
31 Dec 160-1438
31 Dec 150-1136
30 Jun 140-612
31 Mar 140-513

質の高い収益: PYPD is currently unprofitable.

利益率の向上: PYPD is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: PYPD is unprofitable, but has reduced losses over the past 5 years at a rate of 3.1% per year.

成長の加速: Unable to compare PYPD's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: PYPD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


株主資本利益率

高いROE: PYPD has a negative Return on Equity (-1542.91%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘